Dashboard
Manage Tickers

GSKGSK plc

NYSE gsk.com


$ 42.53 $ -1.02 (-2.34 %)    

Tuesday, 17-Sep-2024 15:15:22 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.02 $ -2.95 (-0.62 %)
DIA $ 416.95 $ -1.04 (-0.25 %)
SPY $ 562.37 $ -2.76 (-0.49 %)
TLT $ 100.97 $ -0.42 (-0.41 %)
GLD $ 237.54 $ -0.44 (-0.19 %)
$ 43.55
$ 43.03
$ 42.53 x 100
$ 42.54 x 400
$ 42.51 - $ 43.06
$ 32.11 - $ 45.37
2,417,012
na
93.9B
$ 0.52
$ 14.95
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

japans-ministry-of-health-labour-and-welfare-has-accepted-for-review-gsks-new-drug-application-for-blenrep-belantamab-mafodotin-in-combination-with-bortezomib-plus-dexamethasone-or-pomalidomide-plus-dexamethasone-for-relapsed-or-refractory-multiple-myeloma
Japan's Ministry Of Health, Labour And Wel...
09/17/2024 11:18:22

Core News & Articles
Reported Saturday, iTeos Therapeutics Anno...
09/16/2024 08:47:06

Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with co...

gsk-reveals-positive-data-from-mid-stage-study-of-seasonal-influenza-mrna-vaccine
GSK Reveals 'Positive' Data From Mid-Stage...
09/12/2024 15:32:48

GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.

Core News & Articles
Earlier Today, GSK Announced Headline Resu...
09/12/2024 10:38:01

gsk-confirms-it-has-reached-a-confidential-settlement-with-mr-isaac-dixon-resolving-the-prostate-cancer-case-filed-in-illinois-state-court-gsk-does-not-admit-any-liability-in-this-settlement-the-case-will-now-be-dismissed
GSK Confirms It Has Reached A Confidential...
09/11/2024 16:29:21

- Reuters

gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-biontech
GSK Halts Herpes Simplex Virus Vaccine Dev...
09/11/2024 16:13:09

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clini...

earlier-today-gsks-phase-12-proof-of-concept-study-of-gsk3943104-did-not-meet-the-studys-primary-efficacy-objective-hence-it-will-not-progress-to-phase-3-studies
Earlier Today GSK's Phase 1/2 Proof-Of-Con...
09/11/2024 12:36:26

gsk-announces-depemokimab-late-breaking-data-presented-at-ers-show-a-54-reduction-in-severe-asthma-exacerbations-swift-1-and-swift-2-phase-iii-data-show-depemokimab-delivered-significant-and-clinically-meaningful-reduction-in-exacerbations-over-52-weeks-versus-placebo-plus-standard-of-care-in-duplicate-studies
GSK Announces Depemokimab Late-Breaking Da...
09/09/2024 13:38:54

fda-battles-backlog-of-drug-factory-inspections-since-covid-19
FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

gsks-asthma-drug-meets-main-goal-in-phase-3-study-in-patients-with-smokers-lungs-prepares-competition-with-amgenastrazenecas-drug
GSK's Asthma Drug Meets Main Goal In Phase...
09/06/2024 10:56:44

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

gsks-matinee-phase-3-trial-of-nucala-mepolizumab-met-the-primary-endpoint-showing-a-statistically-significant-and-clinically-meaningful-reduction-in-the-annualized-rate-of-moderatesevere-exacerbations-versus-placebo-in-chronic-obstructive-pulmonary-disease
GSK's MATINEE Phase 3 Trial Of Nucala (Mep...
09/06/2024 09:31:13

gsk-statement-on-zantac-ranitidine-litigation-delaware-supreme-court-to-review-superior-courts-daubert-decision
GSK Statement On Zantac (Ranitidine) Litig...
08/27/2024 18:23:31

- Reuters 

correction-gsk-fda-breakthrough-therapy-news-was-reported-on-august-20
CORRECTION: GSK FDA Breakthrough Therapy N...
08/27/2024 18:12:56

novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets
Novo Nordisk's Ozempic Might Be Among 2027...
08/23/2024 18:21:18

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...

the-fda-has-granted-breakthrough-therapy-designation-to-gsks-gsk5764227-an-investigational-b7-h3-targeted-antibody-drug-conjugate-being-evaluated-for-extensive-stage-small-cell-lung-cancer-with-disease-progression-on-or-after-platinum-based-chemotherapy-relapsed-or-refractory
The FDA Has Granted Breakthrough Therapy D...
08/20/2024 10:34:18

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
08/19/2024 17:35:23

florida-ruling-upholds-gsks-stance-on-once-popular-heart-burn-drug-zantac-not-being-associated-with-cancer-risk
Florida Ruling Upholds GSK's Stance On Onc...
08/16/2024 13:00:55

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a bro...

florida-state-courts-ruling-finds-in-favor-of-gsk-and-other-defendants-excluding-plaintiffs-experts-general-and-specific-causation-testimony-that-ranitidine-was-a-significant-risk-factor-for-wilsons-prostate-cancer
Florida State Court's Ruling Finds In Favo...
08/16/2024 10:25:13

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/15/2024 17:35:23

new-european-regulations-could-hinder-rare-disease-treatments-pharma-industry-raises-concerns-over-stricter-clinical-trial-rules
New European Regulations Could Hinder Rare...
08/13/2024 17:58:57

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION